Scarica l'app Stockscreener
19.99
0.99%
-0.20
Pre-mercato:
20.53
0.54
+2.70%
Precedente Chiudi:
$20.19
Aprire:
$20.19
Volume 24 ore:
503.30K
Relative Volume:
0.85
Capitalizzazione di mercato:
$834.63M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.79%
1M Prestazione:
+42.48%
6M Prestazione:
+360.60%
1 anno Prestazione:
+360.60%
Intervallo 1D:
$19.31
$20.25
Intervallo di 1 settimana:
$19.31
$21.50
Portata 52W:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Nome
Bioage Labs Inc
Settore
Telefono
510-806-1445
Indirizzo
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
19.99 | 842.98M | 0 | 0 | 0 | 0.00 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Piper Sandler | Overweight |
| 2025-12-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-12-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-21 | Iniziato | Citigroup | Buy |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-21 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioage Labs Inc Borsa (BIOA) Ultime notizie
BioAge Labs (NASDAQ:BIOA) Trading Down 5.6%Here's What Happened - MarketBeat
S P Trends: Whats the beta of BioAge Labs Inc stockShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
BioAge Labs (BIOA) Price Target Increased by 127.08% to 27.80 - Nasdaq
Morgan Stanley Boosts Price Target on BioAge Labs to $23 From $12, Keeps Equalweight Rating - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Insider Sells $139,368.75 in Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen - MarketBeat
BioAge Labs (NASDAQ:BIOA) Trading 8% HigherHere's Why - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Pharma Voice
BioAge Labs Completes $115 Million Upsized Public Offering - Global Legal Chronicle
Piper Sandler Initiates Coverage of BioAge Labs (BIOA) with Overweight Recommendation - Nasdaq
Is BioAge Labs Inc.’s ROE strong enough2025 Price Targets & Free Safe Capital Growth Stock Tips - mfd.ru
BioAge Labs (NASDAQ:BIOA) Shares Gap UpShould You Buy? - MarketBeat
Piper Sandler Initiates BioAge Labs at Overweight With $73 Price Target - marketscreener.com
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating - TipRanks
BioAge Labs stock initiated with Overweight rating by Piper Sandler - Investing.com UK
BioAge Labs (NASDAQ:BIOA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Fenwick Represents BioAge Labs in $115M Upsized Public Offering - fenwick.com
Aug PreEarnings: Should you avoid PepsiCo Inc stock right nowEarnings Summary Report & Consistent Profit Trading Strategies - baoquankhu1.vn
BioAge Labs prices upsized stock offering of $115M - MSN
BioAge Labs (NASDAQ:BIOA) Stock Price Down 4.1%Here's What Happened - MarketBeat
BioAge Labs Announces Upsized Public Equity Offering - TipRanks
BioAge Labs Signs Underwriting Agreement With Goldman Sachs, Piper Sandler and Citigroup Global Markets - TradingView
BioAge Labs expands into DME clinical program for oral inhibitor asset - Eyes On Eyecare
BioAge Labs: Early-Stage NLRP3 Opportunity in Ophthalmology and Cardiometabolic Disease Warrants Neutral ‘Hold’ Amid Long Clinical Timelines - TipRanks
BioAge Labs edges down after stock sale hiked to $115 mln - TradingView
BioAge Labs (BIOA) Prices Upsized Public Offering at $19.50, Targeting $115M - Intellectia AI
BioAge Labs prices upsized public offering at $19.50 per share By Investing.com - Investing.com Nigeria
Fund Flows: Is BioAge Labs Inc in accumulation or distribution phase2025 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn
BioAge Labs prices upsized public offering at $19.50 per share - Investing.com
BioAge Announces Pricing of Upsized $115.0 Million Public Offering - Yahoo Finance
Metabolic disease biotech BioAge raises $115M in stock sale - Stock Titan
Dow Update: Will SPDR Gold Trust benefit from rate cutsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Gap DownTime to Sell? - MarketBeat
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
BioAge Announces Proposed $75 Mln Public Offering; Expands BGE-102 Development Into Ophthalmology - Nasdaq
BioAge Labs announces $75 million public stock offering By Investing.com - Investing.com Nigeria
BioAge expands BGE-102 program to diabetic macular edema By Investing.com - Investing.com India
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating - TipRanks
BioAge stock falls after announcing $75 million public offering By Investing.com - Investing.com South Africa
BioAge Labs announces $75 million public stock offering - Investing.com
BioAge Announces Proposed Public Offering - manilatimes.net
BioAge expanding indication for NLRP3 inhibitor BGE-102 into DME - The Pharma Letter
BioAge expands BGE-102 program to diabetic macular edema - Investing.com
BioAge Labs advances BGE-102 into ophthalmology clinical trials - TipRanks
BioAge Labs, Inc. Expands Indication for BGE-102 to Diabetic Macular Edema - TradingView — Track All Markets
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - The Manila Times
Pill for diabetic eye swelling: BioAge tests oral alternative to eye injections - stocktitan.net
Bioage Labs Inc Azioni (BIOA) Dati Finanziari
Non sono disponibili dati finanziari per Bioage Labs Inc (BIOA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):